TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 RESEARCH METHODOLOGY
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 SECONDARY SOURCES
2.8 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 INCREASING PREVALENCE OF SKIN DISEASE OR CONDITION
3.1.2 RISING AGING POPULATION
3.1.3 GROWTH IN TOPICAL DRUG DELIVERY
3.1.4 INCREASING RESEARCH AND DEVELOPMENT OF NEW DERMATOLOGICAL DRUGS
3.1.5 NEW PRODUCT LAUNCHES
3.2 RESTRAINTS
3.2.1 WEAK REIMBURSEMENT POLICIES
3.2.2 REGULATORY SCENARIO AND PRICING PRESSURE
3.3 OPPORTUNITIES
3.3.1 LOW BIOLOGIC PENETRATION
3.3.2 INCREASED COMPETITION LEADING TO HIGH INVESTMENTS IN R&D TO INNOVATE NEW PRODUCTS
3.3.3 INCREASING MERGERS AND ACQUISITIONS
3.3.4 EMERGING MARKET
3.4 CHALLENGES
3.4.1 SIDE EFFECTS
3.4.2 PRODUCT RECALL
3.4.3 HIGH COMPETITION
3.4.4 PENETRATION INTO THE SMALLER MARKETS
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 NORTH AMERICA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 SOLID
6.2.1 POWDER
6.2.2 OTHERS
6.3 SEMI-SOLID
6.3.1 CREAMS
6.3.2 GEL
6.3.3 OINTMENTS
6.3.4 PASTE
6.3.5 OTHERS
6.4 LIQUID
6.4.1 SOLUTION
6.4.2 EMULSION
6.4.3 SUSPENSION
6.4.4 LOTION
6.4.5 OTHERS
7 NORTH AMERICA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 SKIN INFECTIONS
7.3 DERMATITIS
7.4 ANTIAGING
7.5 ACNE
7.6 HYPERPIGMENTATION
7.7 ROSACEA
7.8 SKIN CANCER
7.9 PSORIASIS
7.10 ONYCHOMYCOSIS
7.11 OTHERS
8 NORTH AMERICA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY
8.1 OVERVIEW
8.2 BRANDED
8.3 GENERIC
9 NORTH AMERICA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY GEOGRAPHY
9.1 NORTH AMERICA
9.1.1 U.S.
9.1.2 CANADA
9.1.3 MEXICO
10 NORTH AMERICA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, COMPANY LANDSCAPE
10.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
11 COMPANY PROFILES
11.1 GLAXOSMITHKLINE
11.1.1 COMPANY OVERVIEW
11.1.2 REVENUE ANALYSIS
11.1.3 COMPANY SHARE ANALYSIS
11.1.4 GEOGRAPHICAL PRESENCE
11.1.5 PRODUCT PORTFOLIO
11.1.6 RECENT DEVELOPMENT
11.2 PFIZER INC.
11.2.1 COMPANY OVERVIEW
11.2.2 REVENUE ANALYSIS
11.2.3 COMPANY SHARE ANALYSIS
11.2.4 GEOGRAPHICAL PRESENCE
11.2.5 PRODUCT PORTFOLIO
11.2.6 RECENT DEVELOPMENTS
11.3 GALDERMA LABORATORIES, L.P.
11.3.1 COMPANY OVERVIEW
11.3.2 COMPANY SHARE ANALYSIS
11.3.3 GEOGRAPHICAL PRESENCE
11.3.4 PRODUCT PORTFOLIO
11.3.5 RECENT DEVELOPMENTS
?
11.4 LEO PHARMA A/S
11.4.1 COMPANY OVERVIEW
11.4.2 REVENUE ANALYSIS
11.4.3 COMPANY SHARE ANALYSIS
11.4.4 GEOGRAPHICAL PRESENCE
11.4.5 PRODUCT PORTFOLIO
11.4.6 RECENT DEVELOPMENTS
11.5 BAUSCH HEALTH COMPANIES INC.
11.5.1 COMPANY OVERVIEW
11.5.2 REVENUE ANALYSIS
11.5.3 COMPANY SHARE ANALYSIS
11.5.4 GEOGRAPHICAL PRESENCE
11.5.5 PRODUCT PORTFOLIO
11.5.6 RECENT DEVELOPMENT
11.6 ALLERGAN
11.6.1 COMPANY OVERVIEW
11.6.2 REVENUE ANALYSIS
11.6.3 COMPANY SHARE ANALYSIS
11.6.4 GEOGRAPHICAL PRESENCE
11.6.5 PRODUCT PORTFOLIO
11.6.6 RECENT DEVELOPMENTS
11.7 3M
11.7.1 COMPANY OVERVIEW
11.7.2 REVENUE ANALYSIS
11.7.3 GEOGRAPHICAL PRESENCE
11.7.4 PRODUCT PORTFOLIO
11.7.5 RECENT DEVELOPMENT
11.8 BAYER AG
11.8.1 COMPANY OVERVIEW
11.8.2 REVENUE ANALYSIS
11.8.3 GEOGRAPHICAL PRESENCE
11.8.4 PRODUCT PORTFOLIO
11.8.5 RECENT DEVELOPMENTS
11.9 CIPLA INC.
11.9.1 COMPANY OVERVIEW
11.9.2 REVENUE ANALYSIS
11.9.3 GEOGRAPHICAL PRESENCE
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPMENT
?
11.10 HISAMITSU PHARMACEUTICAL CO., INC.
11.10.1 COMPANY OVERVIEW
11.10.2 REVENUE ANALYSIS
11.10.3 GEOGRAPHICAL PRESENCE
11.10.4 PRODUCT PORTFOLIO
11.10.5 RECENT DEVELOPMENT
11.11 KAKEN PHARMACEUTICAL CO.,LTD.
11.11.1 COMPANY OVERVIEW
11.11.2 REVENUE ANALYSIS
11.11.3 GEOGRAPHICAL PRESENCE
11.11.4 PRODUCT PORTFOLIO
11.11.5 RECENT DEVELOPMENTS
11.12 THE LUBRIZOL CORPORATION
11.12.1 COMPANY OVERVIEW
11.12.2 GEOGRAPHICAL PRESENCE
11.12.3 PRODUCT PORTFOLIO
11.12.4 RECENT DEVELOPMENT
12 RELATED REPORTS